These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30356113)

  • 21. A high-fat diet suppresses de novo lipogenesis and desaturation but not elongation and triglyceride synthesis in mice.
    Duarte JA; Carvalho F; Pearson M; Horton JD; Browning JD; Jones JG; Burgess SC
    J Lipid Res; 2014 Dec; 55(12):2541-53. PubMed ID: 25271296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine-induced nonalcoholic fatty liver disease: The effects of differential food pattern and the involvement of PGRMC1 signaling.
    Zhu Z; Cao T; Chen H; Zhang B; Lin C; Cai H
    Food Chem Toxicol; 2023 Jun; 176():113757. PubMed ID: 37019375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic depletion of Soat2 diminishes hepatic steatosis via genes regulating de novo lipogenesis and by GLUT2 protein in female mice.
    Ahmed O; Pramfalk C; Pedrelli M; Olin M; Steffensen KR; Eriksson M; Parini P
    Dig Liver Dis; 2019 Jul; 51(7):1016-1022. PubMed ID: 30630736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.
    Han X; Cui ZY; Song J; Piao HQ; Lian LH; Hou LS; Wang G; Zheng S; Dong XX; Nan JX; Wu YL
    Chem Biol Interact; 2019 Sep; 311():108794. PubMed ID: 31421115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acyl-Coenzyme A Thioesterase 9 Traffics Mitochondrial Short-Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver.
    Steensels S; Qiao J; Zhang Y; Maner-Smith KM; Kika N; Holman CD; Corey KE; Bracken WC; Ortlund EA; Ersoy BA
    Hepatology; 2020 Sep; 72(3):857-872. PubMed ID: 32498134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation.
    Li H; Ying H; Hu A; Hu Y; Li D
    Biol Pharm Bull; 2017; 40(5):650-657. PubMed ID: 28458350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of an insulin-induced gene binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting sterol regulatory element-binding protein-mediated lipogenesis.
    Jiang SY; Yang X; Yang Z; Li JW; Xu MQ; Qu YX; Tang JJ; Li YF; Wang L; Shao YW; Meng XY; Hu H; Song BL; Rao Y; Qi W
    Hepatology; 2022 Nov; 76(5):1466-1481. PubMed ID: 35102596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Smurf1 aggravates non-alcoholic fatty liver disease by stabilizing SREBP-1c in an E3 activity-independent manner.
    Zhang X; Zhan Y; Lin W; Zhao F; Guo C; Chen Y; Du M; Li D; Zhang L; An W; Wang HR; Xie P
    FASEB J; 2020 Jun; 34(6):7631-7643. PubMed ID: 32301540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
    Ideta T; Shirakami Y; Miyazaki T; Kochi T; Sakai H; Moriwaki H; Shimizu M
    Int J Mol Sci; 2015 Dec; 16(12):29207-18. PubMed ID: 26670228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
    Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M
    World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis.
    Okuma C; Ohta T; Tadaki H; Ishigure T; Sakata S; Taniuchi H; Sano R; Hamada H; Kume S; Nishiu J; Kakutani M
    J Pharmacol Sci; 2015 Jul; 128(3):150-7. PubMed ID: 26215699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms.
    Bitter A; Rümmele P; Klein K; Kandel BA; Rieger JK; Nüssler AK; Zanger UM; Trauner M; Schwab M; Burk O
    Arch Toxicol; 2015 Nov; 89(11):2089-103. PubMed ID: 25182422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver fat accumulation is associated with circulating PCSK9.
    Ruscica M; Ferri N; Macchi C; Meroni M; Lanti C; Ricci C; Maggioni M; Fracanzani AL; Badiali S; Fargion S; Magni P; Valenti L; Dongiovanni P
    Ann Med; 2016 Aug; 48(5):384-91. PubMed ID: 27222915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventive effect of trans-chalcone on non-alcoholic steatohepatitis: Improvement of hepatic lipid metabolism.
    Karimi-Sales E; Ebrahimi-Kalan A; Alipour MR
    Biomed Pharmacother; 2019 Jan; 109():1306-1312. PubMed ID: 30551380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation.
    Cui CX; Deng JN; Yan L; Liu YY; Fan JY; Mu HN; Sun HY; Wang YH; Han JY
    J Ethnopharmacol; 2017 Aug; 208():24-35. PubMed ID: 28648927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiological Disturbance in Fatty Liver Energy Metabolism Converges on IGFBP2 Abundance and Regulation in Mice and Men.
    Fahlbusch P; Knebel B; Hörbelt T; Barbosa DM; Nikolic A; Jacob S; Al-Hasani H; Van de Velde F; Van Nieuwenhove Y; Müller-Wieland D; Lapauw B; Ouwens DM; Kotzka J
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32532003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of NF-κB activation by PDLIM2 restrains hepatic lipogenesis and inflammation in high fat diet induced mice.
    Hao YR; Tang FJ; Zhang X; Wang H
    Biochem Biophys Res Commun; 2018 Sep; 503(2):564-571. PubMed ID: 29852170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.